ReviewWorld journal of urology2017
Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?
Review in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05649943 (APPROACH), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
APPROACH : Multimodal Approach in Patients With mHSPC. A Pragmatic Randomized Trial of Apalutamide Plus Androgen Deprivation Therapy (APA-ADT) Versus APA-ADT Plus Local Treatment. A Meet-URO 29 Study
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- The Effect of Local Therapy on M1c Prostate Cancer Patients: A Systematic Review and Meta-Analysis.Frontiers in surgery · 2021Pooled it
- The role of radical prostatectomy for the treatment of metastatic prostate cancer: a systematic review and meta-analysis.Bioscience reports · 2018Pooled it
- Association of primary tumor surgery with survival outcomes in patients with bone metastases across multiple cancer types.Archives of orthopaedic and trauma surgery · 2026Article
- Prostatic Artery Embolization in Patients with Advanced Prostate Cancer: A Prospective Single Center Pilot Study.Cardiovascular and interventional radiology · 2024Article
- Develop prediction model to help forecast advanced prostate cancer patients' prognosis after surgery using neural network.Frontiers in endocrinology · 2024Article
- Article
- Changing nationwide trends away from overtreatment among patients undergoing radical prostatectomy over the past 25 years.World journal of urology · 2023Article
- Primary Tumor Resection Decelerates Disease Progression in an Orthotopic Mouse Model of Metastatic Prostate Cancer.Cancers · 2022Article
- Nomograms predict survival benefits of radical prostatectomy and chemotherapy for prostate cancer with bone metastases: A SEER-based study.Frontiers in oncology · 2022Article
- Review
- The Role of Radical Prostatectomy and Lymph Node Dissection in Clinically Node Positive Patients.Frontiers in oncology · 2019Review
- The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score is a Novel Significant Prognostic Factor for Patients with Metastatic Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy.Journal of Cancer · 2019Article
- Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far?Prostate cancer · 2018Review
- Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary.Current urology reports · 2017Review
- Radical prostatectomy in locally advanced cancer - an indispensable onset of multimodal therapy?Central European journal of urology · 2017Article
- Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome.Ecancermedicalscience · 2017Article
- Building bridges in urothelial carcinoma to face common challenges.Translational andrology and urology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSurgical removal of the primary tumor in metastatic prostate cancer (mPCa) is becoming a hotly debated issue. The purpose of this review was to summarize the current knowledge on cytoreductive radical prostatectomy (cRP) in this setting. MATERIALS AND
methodsWe performed a non-systematic Medline/PubMed literature search of articles published in the field between January 2000 and April 2015.
resultsCytoreductive surgery has demonstrated its benefit in various malignancies with a solid biological rationale to justify its assessment in mPCa. cRP appears as a safe and feasible procedure in expert hands and well-selected patients. A growing body of evidence suggests a survival benefit for patients undergoing cRP as a part of a multimodal approach compared to those treated with systemic treatment alone. Nevertheless, little is known about the best clinical and tumor characteristics for the selection of patients most likely to benefit from cRP. The current literature is based on retrospective studies with small cohorts and limited follow-up or large uncontrolled population-based studies.
conclusionsData from various other malignancies together with the biological rationale and preliminary results in PCa suggest that cytoreductive surgery may be an option in some mPCa patients. The lack of randomized controlled trials and the low level of evidence in the current literature preclude any firms conclusion on the benefit of cRP in mPCa. Ongoing phase II and future phase III studies are mandatory to define the exact role of cRP in mPCa and to identify the patients who are most likely to benefit from cRP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.